Antisense approaches for inhibiting respiratory syncytial virus

Expert Opinion on Biological Therapy

Volumn 5, Issue 2, 2005, Pages 207-220

  Cramer, Hagen ^a  

^a Ridgeway Biosystems Inc   (United States)

Author keywords

2 5A; 2 5A antisense; Antisense; Antivirals; Aptamer; Interferon; Oligodeoxyribonucleotide; Oligonucleotide; Palivizumab; Phosphorothioate; Ribavirin; RNase L; siRNA

Indexed keywords

2-5A ANTISENSE; ALICAFORSEN; ANTIBODY; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; APTAMER; INTERFERON; OLIGODEOXYRIBONUCLEOTIDE; PALIVIZUMAB; PEGAPTANIB; PHOSPHOROTHIOIC ACID; RIBAVIRIN; RIBONUCLEASE; RIBOZYME; SMALL INTERFERING RNA; SYNTHETASE; UNCLASSIFIED DRUG; VACCINE;

CELL MEMBRANE; COST CONTROL; CROHN DISEASE; DRUG SAFETY; EPITHELIUM CELL; HIGH RISK PATIENT; HUMAN; PARAMYXOVIRUS; PROPHYLAXIS; PROTEIN TARGETING; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RNA INTERFERENCE; ULCERATIVE COLITIS; VIRUS INFECTION; VIRUS MORPHOLOGY; VIRUS REPLICATION;

ANIMALS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 15244341661     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.2.207     Document Type: Review

References (133)

1. COLLINS CL, POLLARD AJ: Respiratory syncytial virus infections in children and adults. J. Infect. (2002) 45(1):10-17.
2. HALL CB: Nosocomial respiratory syncytial virus infections: the 'Cold War' has not ended. Clin. Infect. Dis. (2000) 31(2):590-596.
3. GLEZEN WP, TABER LH, FRANK AL, KASEL JA: Risk of primary infecrion and reinfection with respiratory syncytial virus. Am. J. Dis. Child. (1986) 140(6):543-546.
4. WYDE PR: Respiratory syncytial virus (RSV) disease and prospects for its control. Antiviral Res. (1998) 39(2):63-79.
5. FALSEY AR, WALSH EE: Respiratory syncytial virus infection in adults. Clin. Microbiol. Rev. (2000) 13(3):371-384.
6. THOMPSON WW, SHAY DK, WEINTRAUB E et al.: Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA (2003) 289(2):179-186.
7. COLLINS PL, CHANOCK RH, MCINTOSH K: Respiratory syncytial virus. In: Fields Virology. Fields BN, Knipe DM (Eds), Lippincott-Raven, Philadelphia, PA, USA (1996):1313-1351. Excellent review on the molecular biology of RSV.
8. SHAY DK, HOLMAN RC, ROOSEVELT GE, CLARKE MJ, ANDERSON LJ: Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J. Infect. Dis. (2001) 183(1):16-22.
9. ZAMBON MC, STOCKTON JD, CLEWLEY JP, FLEMING DM: Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet (2001) 358(9291):1410-1416.
10. RUEF C: Respiratory syncytial virus infections-an underdiagnosed entity? Infection (2002) 30(4): 185.
11. HAN LL, ALEXANDER JP, ANDERSON LJ: Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J. Infect. Dis. (1999) 179(1):25-30.
12. MAGGON K, BARIK S: New drugs and treatment for respiratory syncytial virus. Rev. Med. Virol. (2004) 14(3):149-168. Recent comprehensive review on drugs and vaccines against RSV in early and late stage development.
13. PARAMORE LC, CIURYLA V, CIESLA G, LIU L: Economic impact of respiratory syncytial virus-related illness in rhe US: an analysis of national databases. Pharmacoeconomics (2004) 22(5):275-284.
14. MARTINEZ FD: Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma. Pediatr. Infect. Dis. J. (2003) 22(2 Suppl.):S76-S82.
15. SIGURS N: Epidemiologic and clinical evidence of a respiratory syncytial virus-reactive airway disease link. Am. J. Respir. Crit. Care Med. (2001) 163(3 Pt 2):S2-S6.
16. HALL CB, LONG CE, SCHNABEL KC: Respiratory syncytial virus infections in previously healthy working adults. Clin. Infect. Dis. (2001) 33(6):792-796.
17. HASHEM M, HALL CB: Respiratory syncytial virus in healthy adults: the cost of a cold. J. Clin. Virol. (2003) 27(1):14-21.
18. HALL CB, DOUGLAS RG JR, GEIMAN JM: Respiratory syncytial virus infections in infants: quantitation and duration of shedding. J. Pediatr. (1976) 89(1):11-15.
19. DOMINGUEZ KD, MERCIER RC: Treatment of RSV pneumonia in adults-evidence of ribavirin effectiveness? Ann. Pharmacother. (1999) 33(6):739-741.
20. VUJOVIC O, MILLS J: Preventive and therapeutic strategies for respiratory syncytial virus infection. Curr. Opin. Pharmacol. (2001) 1(5):497-503.
21. WHIMBEY E, GHOSH S: Respiratory syncytial virus infections in immunocompromised adults. Curr. Clin. Top. Infect. Dis. (2000) 20:232-255.
22. GREENOUGH A: Respiratory syncytial virus infection: clinical features, management, and prophylaxis. Curr. Opin. Pulm. Med. (2002) 8(3):214-217.
23. KIMPEN JL: Management of respiratory syncytial virus infection. Curr. Opin. Infect. Dis. (2001) 14(3):323-328.
24. EDELL D, KHOSHOO V, ROSS G, SALTER K: Early ribavarin treatment of bronchiolitis: effect on long-term respiratory morbidity. Chest (2002) 122(3):935-939.
25. GUERGUERIAN AM, GAUTHIER M, LEBEL MH, FARRELL CA, LACROIX J: Ribavirin in ventilated respiratory syncytial virus bronchiolitis. A randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. (1999) 160(3):829-834.
26. PATTERSON JL, FERNANDEZ-LARSSON R: Molecular mechanisms of action of ribavirin. Rev. Infect. Dis. (1990) 12(6):1139-1146.
27. FERNANDEZ H, BANKS G, SMITH R: Ribavirin: a clinical overview. Eur. J. Epidemiol. (1986) 2(1):1-14.
28. SIDWELL RW, ROBINS RK, HILLYARD IW: Ribavirin: an antiviral agent. Pharmacol. Ther. (1979) 6(1):123-146.
29. CROTTY S, MAAG D, ARNOLD JJ et al.: The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. (2000) 6(12):1375-1379.
30. ZHOU S, LIU R, BAROUDY BM, MALCOLM BA, REYES GR: The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology (2003) 310(2):333-342.
31. SEVERSON WE, SCHMALJOHN CS, JAVADIAN A, JONSSON CB: Ribavirin causes error catastrophe during Hantaan virus replication. J. Virol. (2003) 77(1):481-488.
32. CROTTY S, CAMERON CE, ANDINO R: RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. USA (2001) 98(12):6895-6900.
33. MALLEY R, DEVINCENZO J, RAMILO O et al.: Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J. Infect. Dis. (1998) 178(6):1555-1561.
34. ROECKL-WIEDMANN I, LIESE JG, GRILL E et al.: Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur. J. Pediatr. (2003) 162(4):237-244.
35. CASIANO-COLON AE, HULBERT BB, MAYER TK, WALSH EE, FALSEY AR: Lack of sensitivity of rapid antigen tests for the diagnosis of respiratory syncytial virus infection in adults. J. Clin. Virol. (2003) 28(2):169-174.
36. SLINGER R, MILK R, GABOURY I, DIAZ-MITOMA F: Evaluation of the QuickLab RSV test, a new rapid lateral-flow immunoassay for detection of respiratory syncytial virus antigen. J. Clin. Microbiol. (2004) 42(8):3731-3733.
37. DOUGLAS JL: In search of a small-molecule inhibitor for respiratory syncytial virus. Expert Rev. Anti Infect. Ther. (2004) 2(4):625-639.
38. WYDE PR: Respiratory syncytial virus. In: Viral Infections and Treatment. Rübsamen-Waigmann H (Ed.), Dekker, New York, USA (2003):91-138.
39. MAGGON K: The ten billion dollar molecule. Pharm. Exec. (2003) 23:60-68.
40. LAMBERT DM, BARNEY S, LAMBERT AL et al.: Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc. Natl. Acad. Sci. USA (1996) 93(5):2186-2191.
41. MEANWELL NA, KRYSTAL M: Respiratory syncytial virus: recent progress towards the discovery of effective prophylactic and therapeutic agents. Drug Discov. Today (2000) 5(6):241-252.
42. MCKIMM-BRESCHKIN J: VP-14637 ViroPharma. Curr. Opin. Investig. Drugs (2000) 1(4):425-427.
43. WEISS WJ, MURPHY T, LYNCH ME et al.; Inhalation efficacy of RFI-641 in an African green monkey model of RSV infection. J. Med. Primatol. (2003) 32(2):82-88.
44. RAZINKOV V, HUNTLEY C, ELLESTAD G, KRISHNAMURTHY G: RSV entry inhibitors block F-protein mediated fusion with model membranes. Antiviral Res. (2002) 55(1):189-200.
45. HUNTLEY CC, WEISS WJ, GAZUMYAN A et al.: RFI-641, a potent respiratory syncytial virus inhibitor. Antimicrob. Agents Chemother. (2002) 46(3):841-847.
46. RAZINKOV V, GAZUMYAN A, NIKITENKO A, ELLESTAD G, KRISHNAMURTHY G: RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein. Chem. Biol. (2001) 8(7):645-659.
47. NIKITENKO AA, RAIFELD YE, WANG TZ: The discovery of RFI-641 as a potent and selective inhibitor of the respiratory syncytial virus. Bioorg. Med. Chem. Lett. (2001) 11(8):1041-1044.
48. SUDO K, WATANABE W, KONNO K et al.: Efficacy of RD3-0028 aerosol treatment against respiratory syncytial virus infection in immunosuppressed mice. Antimicrob. Agents Chemother. (1999) 43(4):752-757.
49. SUDO K, YOSHIDA K, KONNO K et al.: Pharmacokinetics of a benzodithiin (RD3-0028) following aerosol treatment in rat. Xenobiotica (2002) 32(1):19-27.
50. SUDO K, KONNO K, WATANABE W, SHIGETA S, YOKOTA T: Mechanism of selective inhibition of respiratory syncytial virus by a benzodithiin compound (RD3-0028). Microbiol. Immunol. (2001) 45(7):531-537.
51. SUDO K, WATANABE W, MORI S et al.: Mouse model of respiratory syncytial virus infection to evaluate antiviral activity in vivo. Antiviral Chem. Chemother. (1999) 10(3):135-139.
52. WYDE PR, CHETTY SN, TIMMERMAN P, GILBERT BE, ANDRIES K: Short duration aetosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection. Antiviral Res. (2003) 60(3):221-231.
53. ANDRIES K, MOEREMANS M, GEVERS T et al.: Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus. Antiviral Res. (2003) 60(3):209-219.
54. CIANCI C, YU KL, COMBRINK K et al.: Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob. Agents Chemother. (2004) 48(2):413-422.
55. CIANCI C, GENOVESI EV, LAMB L. et al.: Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection. Antimicrob. Agents Chemother. (2004) 48(7):2448-2454.
56. CIANCI C, LANGLEY DR, DISCHINO DD et al.: Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion. Proc. Natl. Acad. Sci. USA (2004) 101(42):15046-15051.
57. WYDE PR, MOORE-POVEDA DK, DE CLERCQ E et al.: Use of cotton rats to evaluate the efficacy of antivirals in treatment of measles virus infections. Antimicrob. Agents Chemother. (2000) 44(5):1146-1152.
58. DE CLERCQ E, COOLS M, BALZARINI J et al.: Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4- carboxamide and related compounds. Antimicrob. Agents Chemother. (1991) 35(4):679-684.
59. WANG G, SAKTHIVEL K, RAJAPPAN V et al.: Synthesis of azole nucleoside 5′-monophosphate mimics (P1Ms) and their inhibitory properties of IMP dehydrogenases. Nucleosides Nucleotides Nucleic Acids (2004) 23(1-2):317-337.
60. WYDE PR, AMBROSE MW, MEYER HL, GILBERT BE: Toxicity and antiviral activity of LY253963 against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats. Antiviral. Res. (1990) 14(4-5):237-247.
61. JAIN J, ALMQUIST SJ, SHLYAKHTER D, HARDING MW: VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J. Pharm. Sci. (2001) 90(5):625-637.
62. MARKLAND W, MCQUAID TJ, JAIN J, KWONG AD: Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob. Agents Chemother. (2000) 44(4):859-866.
63. HAYNES LM, TONKIN J, ANDERSON LJ, TRIPP RA: Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection. J. Virol. (2002) 76(14):6873-6881.
64. OTTOLINI MG, CURTIS SJ, PORTER DD et al.: Comparison of corticosteroids for treatment of respiratory syncytial virus bronchiolitis and pneumonia in cotton rats. Antimicrob. Agents Chemother. (2002) 46(7):2299-2302.
65. PRINCE GA, MATHEWS A, CURTIS SJ, PORTER DD: Treatment of respiratory syncytial virus bronchiolitis and pneumonia in a cotton rat model with systemically administered monoclonal antibody (palivizumab) and glucocorticosteroid. J. Infect. Dis. (2000) 182:1326-1330.
66. GARRISON MM, CHRISTAKIS DA, HARVEY E, CUMMINGS P, DAVIS RL: Systemic corticosteroids in infant bronchiolitis: a meta-analysis. Pediatrics (2000) 105(4):E44.
67. PATEL H, PLATT R, LOZANO JM, WANG EE: Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst. Rev. (2004) (3):CD004878.
68. JOSEY AJ: The development of antiviral therapy and vaccines against respiratory syncytial virus and human parainfluenza virus type 3. Int. J. Pharmaceut. Med. (2001) 15:175-190. Detailed discussion on antiviral therapies in development, sorted by protein or process targeted.
69. CHIN J, MAGOFFIN RL, SHEARER LA, SCHIEBLE JH, LENNETTE EH: Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. (1969) 89(4):449-463.
70. FULGINITI VA, ELLER JJ, SIEBER OF et al.: Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol. (1969) 89(4):435-448.
71. KAPIKIAN AZ, MITCHELL RH, CHANOCK RM, SHVEDOFF RA, STEWART CE: An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol (1969) 89(4):405-421.
72. KIM HW, CANCHOLA JG, BRANDT CD et al.: Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. (1969) 89(4):422-434.
73. DUDAS RA, KARRON RA: Respiratory syncytial virus vaccines. Clin. Microbiol. Rev. (1998) 11(3):430-439.
74. HALL CB: Prospects for a respiratory syncytial virus vaccine. Science (1994) 265(5177):1393-1394.
75. HAYNES LM, JONES LP, BARSKEY A, ANDERSON LJ, TRIPP RA: Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J. Virol. (2003) 77(18):9831-9844.
76. JAFRI HS: Role of chemokines in respiratory syncytial virus disease. Pediatr. Infect. Dis. J. (2002) 21(5):454-456.
77. VARGA SM, BRACIALE TJ: RSV-induced immunopathology: dynamic interplay between the virus and host immune response. Virology (2002) 295(2):203-207.
78. HOLT PG, SLY PD: Interactions between RSV infection, asthma, and atopy: unraveling the complexities. J. Exp. Med. (2002) 196(10):1271-1275.
79. PRINCE GA, CURTIS SJ, YIM KC, PORTER DD: Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J. Gen. Virol. (2001) 82(Pt 12):2881-2888.
80. OPENSHAW PJ, CULLEY FJ, OLSZEWSKA W: Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine (2001) 20(Suppl. 1):S27-S31.
81. MURPHY BR, COLLINS PL: Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. J. Clin. Invest. (2002) 110(1):21-27.
82. KNEYBER MC, KIMPEN JL: Advances in respiratory syncytial virus vaccine development. Curr. Opin. Investig. Drugs (2004) 5(2):163-170.
83. ZHANG L, PEEPLES ME, BOUCHER RC, COLLINS PL, PICKLES RJ: Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J. Virol. (2002) 76(11):5654-5666.
84. BANERJEE AK, BARIK S, DE BP: Gene expression of nonsegmented negative strand RNA viruses. Pharmacol. Ther. (1991) 51(1):47-70.
85. COLLINS PL, DICKENS LE, BUCKLER-WHITE A et al.: Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order. Proc. Natl. Acad. Sci. USA (1986) 83(13):4594-4598.
86. ZAMECNIK P: Background of the antisense oligonucleotide approach to chemotherapy. Antisense Nucleic Acid Drug Dev. (1997) 7(3):199-202.
87. WU-PONG S, BYRON PR: Airway-to-biophase transfer of inhaled oligonucleotides. Adv. Drug Del. Rev. (1996) 19:47-71.
88. TEMPLIN MV, LEVIN AA, GRAHAM MJ et al.: Pharmacokinetic and toxicity profile of a phosphorothioate oligonucleotide following inhalation delivery to lung in mice. Antisense Nucleic Acid Drug Dev. (2000) 10(5):359-368.
89. NYCE JW, METZGER WJ: DNA antisense therapy for asthma in an animal model. Nature (1997) 385(6618):721-725.
90. DEAN NM, BENNETT CF: Antisense oligonucleotide-based therapeutics for cancer. Oncogene (2003) 22(56):9087-9096.
91. PIROLLO KF, RAIT A, SLEER LS, CHANG EH: Antisense therapeutics: from theory to clinical practice. Pharmacol. Ther. (2003) 99(1):55-77.
92. HOLMLUND JT: Applying antisense technology: Affinitak and other antisense oligonucleotides in clinical development. Ann. NY Acad. Sci. (2003) 1002:244-251.
93. CROOKE ST: Therapeutic applications of oligonucleotides. Annu. Rev. Pharmacol. Toxicol. (1992) 32:329-376.
94. CROOKE ST, GRAHAM MJ, ZUCKERMAN JE et al.: Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharm. Exp. Ther. (1996) 277(2):923-937.
95. KURRECK J: Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. (2003) 270(8):1628-1644.
96. JAIRATH S, VARGAS PB, HAMLIN HA, FIELD AK, KILKUSKIE RE: Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides. Antiviral Res. (1997) 33(3):201-213.
97. BURGESS TL, FISHER EF, ROSS SL et al.: The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc. Natl. Acad. Sci. USA (1995) 92(9):4051-4055.
98. SIDDIQUI-JAIN A, GRAND CL, BEARSS DJ, HURLEY LH: Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc. Natl. Acad. Sci. USA (2002) 99(18):11593-11598.
99. VINORES SA: Technology evaluation: pegaptanib, Eyetech/Pfizer. Curr. Opin. Mol. Ther. (2003) 5(6):673-679.
100. EYETECH STUDY GROUP: Antivascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results. Ophthalmology (2003) 110(5):979-986.
101. BITKO V, BARIK S: Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. BMC Microbiol. (2001) 1(1):34.
102. BEHERA AK, MATSUSE H, KUMAR M et al.: Blocking intercellular adhesion molecule-1 on human epithelial cells decreases respiratory syncytial virus infection. Biochem. Biophys. Res. Commun. (2001) 280(1):188-195.
103. YU RZ, SU JQ, GRUNDY JS et al.: Prediction of clinical responses in a simulated Phase III trial of Crohn's patients administered the antisense phosphorothioate oligonucleotide ISIS 2302: comparison of proposed dosing regimens. Antisense Nucleic Acid Drug Dev. (2003) 13(1):57-66.
104. FEFFERMAN DS, FARRELL RJ: Making sense of antisense: ISIS 2302 (alicaforsen) in the treatment of pouchitis. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchits. Inflamm. Bowel Dis. (2004) 10(4):487-488.
105. MINER P, WEDEL M, BANE B, BRADLEY J: An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol. Ther. (2004) 19(3):281-286.
106. YACYSHYN BR: Antisense oligonucleotide treatment of inflammatory bowel diseases. Methods Mol. Med. (2004) 106:295-306.
107. KAHAN BD, STEPKOWSKI S, KILIC M et al.: Phase I and Phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection. Transplantation (2004) 78(6):858-863.
108. PLAYER MR, TORRENCE PF: The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation. Pharmacol. Ther. (1998) 78(2):55-113. Comprehensive review of all aspects of 2-5A, including synthesis and properties of related 2′,5′-linked ONs.
109. SILVERMAN RH: Fascination with 2-5A-dependent RNase: a unique enzyme that functions in interferon action. J. Interferon Res. (1994) 14(3):101-104.
110. STARK GR, KERR IM, WILLIAMS BR, SILVERMAN RH, SCHREIBER RD: How cells respond to interferons. Annu. Rev. Biochem. (1998) 67:227-264. Authoritative review on the mechanisms of IFN action.
111. DONG B, XU L, ZHOU A et al.: Intrinsic molecular activities of the interferon-induced 2-5A-dependent RNase. J. Biol. Chem. (1994) 269(19):14153-14158.
112. TORRENCE PF, MAITRA RK, LESIAK K et al.: Targeting RNA for degradation with a (2′-5′)oligoadenylate-antisense chimera. Proc. Natl. Acad. Sci. USA (1993) 90(4):1300-1304.
113. PLAYER MR, BARNARD DL, TORRENCE PF: Potent inhibition of respiratory syncytial virus replication using a 2-5A-antisense chimera targeted to signals within the virus genomic RNA. Proc. Natl. Acad. Sci. USA (1998) 95(15):8874-8879. Description of 2-5A antisense targeting genomic RNA.
114. BEHERA AK, KUMAR M, LOCKEY RF, MOHAPATRA SS: 2′-5′ Oligoadenylate synthetase plays a critical role in interferon-gamma inhibition of respiratory syncytial virus infection of human epithelial cells. J. Biol. Chem. (2002) 277(28):25601-25608.
115. CIRINO NM, LI G, XIAO W, TORRENCE PF, SILVERMAN RH: Targeting RNA decay with 2′,5′ oligoadenylate-antisense in respiratory syncytial virus-infected cells. Proc. Natl. Acad. Sci. USA (1997) 94(5):1937-1942. First description of inhibition of RSV by 2-5A aritisense, including evidence of specific mRNA destruction.
116. BARNARD DL, SIDWELL RW, XIAO W et al.: 2-5A-DNA conjugate inhibition of respiratory syncytial virus replication: effects of oligonucleotide structure modifications and RNA target site selection. Antiviral Res. (1999) 41(3):119-134.
117. LEAMAN DW, LONGANO FJ, OKICKI JR et al.: Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A antisense. Virology (2002) 292(1):70-77. First in vivo demonstration of the effectiveness of 2-5A antisense in treating RSV infections.
118. SILVERMAN RH: In: Ribonucleases: Structure and Function. D'Alessio G, Riordan JF (Eds), Academic Press, New York, USA (1997):515-551. Comprehensive review of RNase L.
119. TORRENCE PF, XIAO W, LI G et al.: Recruiting the 2-5A system for antisense therapeutics. Antisense Nucleic Acid Drug Dev. (1997) 7(3):203-206.
120. MARAN A, MAITRA RK, KUMAR A et al.: Blockage of NF-kappa B signaling by selective ablation of an mRNA target by 2-5A antisense chimeras. Science (1994) 265:789-792.
121. TORRENCE PF: 2-5A-amisense chimeras: inhibitors of respiratory syncytial virus infection. Curr. Opin. Mol. Ther. (1999) 1(3):307-315. Excellent review describing the strategy for selecting the intergenomic GS sequence and reasons for targeting RSV through the action of RNase L.
122. TORRENCE PF, POWELL LD: The quest for an efficacious antiviral for respiratory syncytial virus. Antiviral Chem. Chemother. (2002) 13(6):325-344. Review describing ribavirin's mechanism of action, and the concept and possible future directions of targeting RSV with 2-5A antisense.
123. XIANG Y, WANG Z, MURAKAMI J et al.: Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2′,5′- oligoadenylates. Cancer Res. (2003) 63(20):6795-6801.
124. TORRENCE PF, IMAI J, JOHNSTON MI: 5′-O- Monophosphoryladenylyl(2′ goes to 5′)adenylyl(2′ goes to 5′)adenosine is an antagonist of the action of 5′-O- triphosphoryladenylyl-(2′ goes to 5′)adenylyl(2′ goes to 5′)adenosine and double-stranded RNA. Proc. Natl. Acad. Sci. USA (1981) 78(10):5993-5997.
125. JOHNSTON MI, TORRENCE PF: The role of interferon-induced proteins, double-stranded RNA, and 2′,5′-oligoadenylate in the interferon-mediated inhibhition of viral translation. In: Interferon: Mechanisms of Production and Action. Friedman RM (Ed.), Elsevier Science, Amsterdam, The Netherlands (1984):189-298.
126. TORRENCE PF: How interferon works. In: Biological Response Modifiers - New Approaches To Disease Intervention. Torrence PF (Ed.), Academic Press, New York, USA (1985):77-105.
127. XU Z, KUANG M, OKICKI JR, CRAMER H, CHAUDHARY N: Potent inhibition of respiratory syncytial virus by combination treatment with 2-5A antisense and ribavirin. Abtiviral Res. (2004) 61(3):195-206.
128. CRAMER H, OKICKI JR, KUANG M, XU Z: Targeted therapy of respiratory syncytial virus by 2-5A antisense. Nucleosides Nucleotides Nucleic Acids (2005) (Submitted).
129. WYDE PR, AMBROSE MW, MEYER HL, ZOLINSKI CL, GILBERT BE: Evaluation of the toxicity and antiviral activity of carbocyclic 3-deazaadenosine against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats. Antiviral Res. (1990) 14(4-5):215-225.
130. KNIGHT V, GILBERT BE, WYDE PR, ENGLUND JA: High dose-short duration ribavirin aerosol treatment-a review. Bull. Int. Union Tuberc. Lung Dis. (1991) 66(2-3):97-101.
131. GILBERT BE, WYDE PR, AMBROSE MW, WILSON SZ, KNIGHT V: Further studies with short duration ribavirin aerosol for the treatment of influenza virus infection in mice and respiratory syncytial virus infection in cotton rats. Antiviral Res. (1992) 17(1):33-42.
132. GILBERT BE, KNIGHT V: Biochemistry and clinical applications of ribavirin. Antimicrob. Agents Chemother. (1986) 30(2):201-205.
133. WYDE PR, WILSON SZ, PETRELLA R, GILBERT BE: Efficacy of high dose-short duration ribavirin aerosol in the treatment of respiratory syncytial virus infected cotton rats and influenza B virus infected mice. Antiviral Res. (1987) 7(4):211-220.